Distribution - In Vitro Tests - Protein Binding

Abstract

The protein binding plays an important role in the pharmacokinetics and pharmacodynamics of a drug. Plasma binding can also be viewed as a circulating site of storage, releasing the drug to tissue with higher affinity. Only the unbound drug is thought to be able to diffuse across membranes and to interact with an effector site to produce a therapeutic response.

Keywords

Human Serum Albumin Plasma Protein Binding Free Fraction Insulin Aspart Unbind Fraction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References and Further Reading

  1. Barre J, Chamouard JM, Houin G, Tillement JP (1985) Equilibrium dialysis, ultrafiltration, and ultracentrifugation compared for determining the plasma-protein-binding characteristics of valproic acid. Clin Chem 31(1):60–64PubMedGoogle Scholar
  2. Benet LZ, Hoener B (2002) Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 71(3):115–121PubMedCrossRefGoogle Scholar
  3. Blodgett J, Lynch J Millipore™, Application Note AN1733EN00: volume determination methods utilized in drug plasma protein binding (PPB) assays, Millipore, Danvers, MA, USA. http://www.millipore.com
  4. Blodgett J, Lynch J Millipore™, Application Note AN1735EN00: evaluation of small molecule non-specific binding, Millipore, Danvers, MA, USA. http://www.millipore.com
  5. Boudoulas S, Lush RM, McCall NA, Samid D, Reed E, Figg WD (1996) Plasma protein binding of phenylacetate and phenylbutyrate, two novel antineoplastic agents. Ther Drug Monit 18:714PubMedCrossRefGoogle Scholar
  6. Bowers WF, Fulton S, Thompson J (1984) Ultrafiltration vs equilibrium dialysis for determination of free fraction. Clin Pharmacokinet 9(Suppl 1):49–60PubMedCrossRefGoogle Scholar
  7. Brørs O, Jacobsen S (1985) pH lability in serum during equilibrium dialysis. Br J Clin Pharmacokinet 20:85–88CrossRefGoogle Scholar
  8. Christensen JH, Andreasen F, Jensen EB (1980) The binding of thiopental to serum proteins determined by ultrafiltration and equilibrium dialysis. Acta Pharmacol Toxicol 47:24–32CrossRefGoogle Scholar
  9. Davies B, Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–1095PubMedCrossRefGoogle Scholar
  10. Echize H, Ishikawa S, Koike K, Ishizaki T (1995) Nomogram for estimating plasma unbound disopyramide concentrations in patients with varying plasma alpha 1-acid glycoprotein concentrations. Ther Drug Monit 17:145CrossRefGoogle Scholar
  11. Faber J, Waetjen I, Siersbaek-Nielsen K (1993) Free thyroxine measured in undiluted serum by dialysis and ultrafiltration: effects on non-thyroidal illness, and an acute load of salicylate or heparin. Clin Chim Acta 223:159–167PubMedCrossRefGoogle Scholar
  12. Fehske KJ, Müller WE, Wollert U (1981) The locations of drug binding sites in human serum albumin. Biochem Pharmacol 30:687–692PubMedCrossRefGoogle Scholar
  13. Fung EN, Chen Y-H, Lau YY (2003) Semi-automatic high throughput of plasma protein binding using 96-well plate filtrate assembly and fast liquid chromatography-tandem mass spectrometry. J Chromatogr B 795:187–194CrossRefGoogle Scholar
  14. Grainger-Rousseau TJ, McElnay JC, Collier PS (1989) The influence of disease on plasma protein binding on drugs. Int J Pharm 54:1–13CrossRefGoogle Scholar
  15. Henricsson S (1987) Equilibrium dialysis in a stainless steel chamber: measurement of the free plasma fraction of cyclosporin. Pharm Pharmacol Commun 6(10):447–450Google Scholar
  16. Hijazi Y, Boulieu R (2002) Protein binding of ketamine and its active metabolites to human serum. Eur J Clin Pharmacol 58:37–40PubMedCrossRefGoogle Scholar
  17. Jack DB (1992) Handbook of clinical pharmacokinetics data. Macmillan, Basingstoke, pp 1–132Google Scholar
  18. Jordan KH, Bruner J, Doan M, Serabjit-Singh C, Wring S (2000) Automated plasma protein binding assay: implementation on a Tecan Genesis 150 and and Zymark RapidPlate. Poster presented at the LIRG Southeast, 25 Oct 2000Google Scholar
  19. Judd RL, Pesce AJ (1982) Free drug concentrations are constant in serial fractions of plasma ultrafiltrates. Clin Chem 28:1726PubMedGoogle Scholar
  20. Kariv I, Cao H, Oldenburg KR (2000) Development of a high throughput equilibrium dialysis method. J Pharma Sci 90:580–587CrossRefGoogle Scholar
  21. Kragh-Hansen U (1990) Structure and ligand binding properties of human serum albumin. Dan Med Bull 37(1):57–84PubMedGoogle Scholar
  22. Kragh-Hansen U, Minchiotti L, Brennan SO, Sugita O (1985) Relation between high affinity binding sites of markers for binding regions on human serum albumin. Biochem J 225:629–638PubMedGoogle Scholar
  23. Kremer JMH, Wilting J, Janssen LHM (1988) Drug binding of human α1-acid glycoprotein in health and disease. Pharmacol Rev 40:1–47PubMedGoogle Scholar
  24. Kurz H, Trunk H, Weitz B (1977) Evaluation of methods to determine protein-binding of drugs. Arzneimittelforschung (Drug Res) 27(7):1373–1380Google Scholar
  25. Lee K-J, Mower R, Hollenbeck T, Castelo J, Johnson N, Gordon P, Sinko PJ, Holme K, Lee YH (2003) Modulation of nonspecific binding in ultrafiltration protein binding studies. Pharm Res 20(7):1015PubMedCrossRefGoogle Scholar
  26. Lima JJ (1988) Species-dependent binding of disopyramide enantiomers. Drug Metab Dispos 16:563PubMedGoogle Scholar
  27. Lima JJ, MacKichan JJ, Libertin N, Sabino J (1983) Influence of volume shifts on drug binding during equilibrium dialysis: correction and attenuation. J Pharmacokinet Biopharm 11(5):483–498PubMedCrossRefGoogle Scholar
  28. Lin JH, DeLuna FA, Ulm EH, Tocco DJ (1990) Species-dependent enantioselective plasma protein binding of MK-571, a potent leukotriene D4 antagonist. Drug Metabolism Disposition 18:484Google Scholar
  29. Lin JH, Ulm EH, Los LE (1991) Dose-dependent stereo-pharmacokinetics of 5, 6-dihydro-4H-4 (isobutylamino)thieno(2,3-B)thiopyran-2-sulfonamide-7,7 -dioxide, a potent carbonic anhydrase inhibitor, in rats. Drug Metab Dispos 19:233PubMedGoogle Scholar
  30. Mahmood J (2000) Interspecies scaling: role of protein binding in the prediction of clearance from animals to humans. J Clin Pharmacol 40:1439–1446PubMedCrossRefGoogle Scholar
  31. Mapleson WW (1987) Computation of the effect of Donnan equilibrium on pH in equilibrium dialysis. J Pharmacol Methods 17(3):231–242PubMedCrossRefGoogle Scholar
  32. Mayer LD, St-Onge G (1995) Determination of free and liposome-associated doxorubicin and vincristine levels in plasma under equilibrium conditions employing ultrafiltration techniques. Anal Biochem 232:149PubMedCrossRefGoogle Scholar
  33. Muller WE (1989) Drug binding site on human α1-acid glycoprotein. Prog Clin Biol Res 300:363–378PubMedGoogle Scholar
  34. Nakai D, Kumamoto K, Sakikawa C, Kosaka T, Tokui T (2003) Evaluation of the protein binding ratio of drugs by a micro-scale ultracentrifugation method. J Pharm Sci 93:847CrossRefGoogle Scholar
  35. Norris RLG, Ahokas JT, Ravenscroft PJ (1982) Determination of unbound fraction of disopyramide in plasma: a comparison of equilibrium dialysis, ultrafiltration through dialysis membranes and ultrafree anticonvulsant drug filters. J Pharmacol Methods 7(1):7–14PubMedCrossRefGoogle Scholar
  36. Notarianni LJ (1990) Plasma protein binding of drugs in pregnancy and in neonates. Clin Pharmacokinet 18(1):20–36PubMedCrossRefGoogle Scholar
  37. Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and non-specific binding to microsomes. Drug Metab Dispos 27(11):1350–1359PubMedGoogle Scholar
  38. Obach RS, Baxter JG, Liston TE, Silber MB, Jones BC, MacIntyre F, Rance DJ, Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283(1):46–58PubMedGoogle Scholar
  39. Oravcová J, Böhs B, Lindner W (1995) Drug-protein studies: new trends in analytical and experimental methodology. J Chromatogr 677:1–28Google Scholar
  40. Pacifici GM, Viani A (1992) Methods of determining plasma and tissue binding of drugs. Clin Pharmacokinet 23(6):449–468PubMedCrossRefGoogle Scholar
  41. Pang KS, Rowland M (1977) Hepatic clearance of drugs. I. Theoretical consideration of a “well-stirred” model and a “parallel tube” model: influence of hepatic blood flow, plasma and blood cell binding, and to the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 5:625–653PubMedCrossRefGoogle Scholar
  42. Plum A, Larsen PS, Larsen UD, Kristensen JB, Jansen JA (1999) Determination of in vitro plasma protein binding of insulin aspart and insulin detemir by equilibrium dialysis. Poster presented at the 35th annual meeting of EASD Brussels, Belgium, Sept 1999Google Scholar
  43. Plum A, Müller LK, Jansen JA (2000) The effects of selected drugs on the in vitro protein binding of repaglinide in human plasma. Methods Find Exp Clin Pharmacol 22(3):129–143Google Scholar
  44. Robieux I, Aita P, Sorio R, Toffoli G, Boiocchi M (1997) Determination of unbound etoposide concentration in ultrafiltered plasma by high-performance liquid chromatography with fluorimetric detection. J Chromatogr 686:35Google Scholar
  45. Rolan PE (1994) Plasma protein binding displacement interactions – why are they still regarded as clinically important? Br J Clin Pharmacol 37:125–128PubMedCrossRefGoogle Scholar
  46. Rosenthal AE (1967) A graphic method for the determination and presentation of binding parameters in a complex system. Anal Biochem 20:525–532PubMedCrossRefGoogle Scholar
  47. Rowland M, Tozer TN (1995) Clinical pharmacokinetics: concepts and applications, 3rd edn. Williams & Wilkins, Baltimore, p 142Google Scholar
  48. Sansom LN, Evans AM (1995) What is the true clinical significance of plasma protein binding displacement interactions? Drug Saf 12(4):227–233PubMedCrossRefGoogle Scholar
  49. Scatchard G (1949) The attractions of protein for small molecules and ions. Ann N Y Acad Sci 51:660–692CrossRefGoogle Scholar
  50. Schuhmacher J, Bühner K, Witt-Laido A (2000) Determination of the free fraction and relative free fraction of drugs strongly bound to plasma proteins. J Pharm Sci 89:8CrossRefGoogle Scholar
  51. Schumacher J, Kohlsdorfer C, Bühner K, Brandenburger T, Kruk R (2004) High-throughput determination of the free fraction of drugs strongly bound to plasma proteins. J Pharm Sci 93:816–830CrossRefGoogle Scholar
  52. Steinberg IZ, Schachman HK (1966) Ultracentrifugation studies with absorption optics. V. Analysis of interacting systems involving macromolecules and small molecules. Biochemistry 5(12):3728CrossRefGoogle Scholar
  53. Tozer TN, Gambertoglio JG, Furst DE, Avery DS, Holford NH (1983) Volume shift and protein binding estimates using equilibrium dialysis: application to prednisolone binding in humans. J Pharm Sci 72(12):1442–1446PubMedCrossRefGoogle Scholar
  54. Urien S, Tillement JP, Barré J (2001) The significance of plasma-protein binding in drug research. In: Testa B et al (eds) Pharmacokinetic optimization in drug research, 1st edn. Wiley-VCH, New York, p 189CrossRefGoogle Scholar
  55. Verbeeck RK, Cardinal J (1985) Plasma protein binding of salicylic acid, phenytoin, chlorpromazine, propranolol and pethidine using equilibrium dialysis and ultracentrifugation. Arzneimittelforschung 35:903PubMedGoogle Scholar
  56. Verbeeck RK, Cardinal JA, Wallace SM (1984) Effect of age and sex on the plasma binding of acidic and basic drugs. Eur J Clin Pharmacol 27(1):91–97PubMedGoogle Scholar
  57. Wilkins JN, Ashofteh A, Setoda D, Wheatley WS, Huigen H, Ling W (1997) Ultrafiltration using the Amicon MPS-1 for assessing methadone plasma protein binding. Ther Drug Monit 19:83–87PubMedCrossRefGoogle Scholar
  58. Wilkinson GR, Shand DG (1975) A physiological approach to hepatic drug clearance. Clin Pharm Ther 18:377–380Google Scholar
  59. Withlam JB, Brown KF (1981) Ultrafiltration in serum protein binding determinations. J Pharm Sci 70:146–150CrossRefGoogle Scholar
  60. Wright JF, Boudinot DF, Ujhelyi MR (1996) Measurement and analysis of unbound drug concentrations. Clin Pharmacokinet 30(6):445–462PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Sanofi Deutschland GmbHFrankfurt am MainGermany

Personalised recommendations